Cargando…

Cell-Based High-Throughput Screening Protocol for Discovering Antiviral Inhibitors Against SARS-COV-2 Main Protease (3CLpro)

The global public health has been compromised since the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) emerged in late December 2019. There are no specific antiviral drugs available to combat SARS-CoV-2 infection. Besides the rapid dissemination of SARS-CoV-2, several variants have bee...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rothan, Hussin A., Teoh, Teow Chong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2021
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7814170/ https://www.ncbi.nlm.nih.gov/pubmed/33464543 http://dx.doi.org/10.1007/s12033-021-00299-7

Ejemplares similares

Discovery of 3CLpro inhibitor of SARS-CoV-2 main protease
por: Kuang, Yi, et al.
Publicado: (2023)

Antiviral evaluation of hydroxyethylamine analogs: Inhibitors of SARS-CoV-2 main protease (3CLpro), a virtual screening and simulation approach
por: Gupta, Yash, et al.
Publicado: (2021)

High Throughput Virtual Screening to Discover Inhibitors of the Main Protease of the Coronavirus SARS-CoV-2
por: Olubiyi, Olujide O., et al.
Publicado: (2020)

Doxycycline Interferes with Zika Virus Serine Protease and Inhibits Virus Replication in Human Skin Fibroblasts
por: Chong Teoh, Teow, et al.
Publicado: (2021)

A Study of Drug Repurposing to Identify SARS-CoV-2 Main Protease (3CLpro) Inhibitors
por: Jo, Seri, et al.
Publicado: (2022)

The main protease 3CLpro of the SARS-CoV-2 virus: how to turn an enemy into a helper
por: Belenkaya, Svetlana V., et al.
Publicado: (2023)

Rutin Is a Low Micromolar Inhibitor of SARS-CoV-2 Main Protease 3CLpro: Implications for Drug Design of Quercetin Analogs
por: Rizzuti, Bruno, et al.
Publicado: (2021)

Multistep rational molecular design and combined docking for discovery of novel classes of inhibitors of SARS-CoV-2 main protease 3CLpro
por: Tumskiy, Roman S., et al.
Publicado: (2021)

Dimethyl sulfoxide reduces the stability but enhances catalytic activity of the main SARS‐CoV‐2 protease 3CLpro
por: Ferreira, Juliana C., et al.
Publicado: (2021)

Key dimer interface residues impact the catalytic activity of 3CLpro, the main protease of SARS-CoV-2
por: Ferreira, Juliana C., et al.
Publicado: (2022)

Corrigendum: The main protease 3CLpro of the SARS-CoV-2 virus: how to turn an enemy into a helper
por: Belenkaya, Svetlana V., et al.
Publicado: (2023)

Biochemical and biophysical characterization of the main protease, 3-chymotrypsin-like protease (3CLpro) from the novel coronavirus SARS-CoV 2
por: Ferreira, Juliana C., et al.
Publicado: (2020)

High-throughput screening of SARS-CoV-2 main and papain-like protease inhibitors
por: Zang, Yi, et al.
Publicado: (2022)

In Silico Identification of Potential Inhibitors of the SARS-CoV-2 Main Protease among a PubChem Database of Avian Infectious Bronchitis Virus 3CLPro Inhibitors
por: Soulère, Laurent, et al.
Publicado: (2023)

Protocol for high-throughput screening of SARS-CoV-2 main protease inhibitors using a robust fluorescence polarization assay
por: Zhang, Jing, et al.
Publicado: (2022)

Dual inhibition of COVID-19 spike glycoprotein and main protease 3CLpro by Withanone from Withania somnifera
por: Patil, Vishal Shivalingappa, et al.
Publicado: (2021)

Biflavonoid as potential 3-chymotrypsin-like protease (3CLpro) inhibitor of SARS-Coronavirus
por: Hartini, Yustina, et al.
Publicado: (2021)

Structure-Based Virtual Screening and Biochemical Validation to Discover a Potential Inhibitor of the SARS-CoV-2 Main Protease
por: Gupta, Akshita, et al.
Publicado: (2020)

Screening marine algae metabolites as high-affinity inhibitors of SARS-CoV-2 main protease (3CLpro): an in silico analysis to identify novel drug candidates to combat COVID-19 pandemic
por: Muteeb, Ghazala, et al.
Publicado: (2020)

Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents
por: Mody, Vicky, et al.
Publicado: (2021)

NMDA receptor antagonism with novel indolyl, 2-(1,1-Dimethyl-1,3-dihydro-benzo[e]indol-2-ylidene)-malonaldehyde, reduces seizures duration in a rat model of epilepsy
por: Rothan, Hussin A., et al.
Publicado: (2017)

Targeting the Main Protease of SARS‐CoV‐2: From the Establishment of High Throughput Screening to the Design of Tailored Inhibitors
por: Breidenbach, Julian, et al.
Publicado: (2021)

A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV2 main protease
por: Baker, Jeremy D., et al.
Publicado: (2021)

Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of Nsp5 main protease
por: Milligan, Jennifer C., et al.
Publicado: (2021)

Structure-based virtual screening and molecular dynamics simulation studies to discover new SARS-CoV-2 main protease inhibitors
por: Ibezim, A., et al.
Publicado: (2021)

Bisindolylmaleimide IX: A novel anti-SARS-CoV2 agent targeting viral main protease 3CLpro demonstrated by virtual screening pipeline and in-vitro validation assays
por: Gupta, Yash, et al.
Publicado: (2021)

Structural stability of SARS-CoV-2 3CLpro and identification of quercetin as an inhibitor by experimental screening
por: Abian, Olga, et al.
Publicado: (2020)

Biochemical screening for SARS-CoV-2 main protease inhibitors
por: Coelho, Camila, et al.
Publicado: (2020)

A Combination of Doxycycline and Ribavirin Alleviated Chikungunya Infection
por: Rothan, Hussin A., et al.
Publicado: (2015)

Design, synthesis and antiviral efficacy of a series of potent chloropyridyl ester-derived SARS-CoV 3CLpro inhibitors
por: Ghosh, Arun K., et al.
Publicado: (2008)

A VSV-based assay quantifies coronavirus Mpro/3CLpro/Nsp5 main protease activity and chemical inhibition
por: Heilmann, Emmanuel, et al.
Publicado: (2022)

A highly sensitive cell-based luciferase assay for high-throughput automated screening of SARS-CoV-2 nsp5/3CLpro inhibitors
por: Chen, K.Y., et al.
Publicado: (2022)

A highly sensitive cell-based luciferase assay for high-throughput automated screening of SARS-CoV-2 nsp5/3CLpro inhibitors
por: Chen, KY, et al.
Publicado: (2021)

TAT-peptide conjugated repurposing drug against SARS-CoV-2 main protease (3CLpro): Potential therapeutic intervention to combat COVID-19
por: Ansari, Mohammad Azam, et al.
Publicado: (2020)

Structural and Biochemical Analysis of the Dual Inhibition of MG-132 against SARS-CoV-2 Main Protease (Mpro/3CLpro) and Human Cathepsin-L
por: Costanzi, Elisa, et al.
Publicado: (2021)

Development of Highly Potent Noncovalent Inhibitors of SARS-CoV-2 3CLpro
por: Hou, Ningke, et al.
Publicado: (2023)

Progress on SARS-CoV-2 3CLpro Inhibitors: Inspiration from SARS-CoV 3CLpro Peptidomimetics and Small-Molecule Anti-Inflammatory Compounds
por: Zhu, Jiajie, et al.
Publicado: (2022)

High-throughput screening and evaluation of repurposed drugs targeting the SARS-CoV-2 main protease
por: Li, Yan, et al.
Publicado: (2021)

Optimization of Triarylpyridinone Inhibitors of the Main Protease of SARS-CoV-2 to Low-Nanomolar Antiviral Potency
por: Zhang, Chun-Hui, et al.
Publicado: (2021)

A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antivirals
por: Alugubelli, Yugendar R., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_230aj58hcqom1okon23hr9ke3j